Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Position Lowered by Everstar Asset Management LLC

Everstar Asset Management LLC trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 46.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 216,223 shares of the company’s stock after selling 183,902 shares during the period. Everstar Asset Management LLC owned 0.24% of Aquestive Therapeutics worth $770,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. New York State Common Retirement Fund grew its holdings in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after buying an additional 10,700 shares in the last quarter. PKS Advisory Services LLC purchased a new position in Aquestive Therapeutics during the 4th quarter valued at about $63,000. Intech Investment Management LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at about $90,000. BNP Paribas Financial Markets lifted its position in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth approximately $69,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Down 5.9 %

Shares of AQST stock opened at $3.02 on Monday. Aquestive Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $5.80. The company has a market cap of $298.59 million, a PE ratio of -6.71 and a beta of 2.76. The business’s 50 day moving average is $2.99 and its two-hundred day moving average is $3.94.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. As a group, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AQST. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, March 10th. Lake Street Capital reduced their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Cantor Fitzgerald began coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.